Establishment and gene expression analysis of disease-derived induced pluripotent stem cells of scleroderma

Journal of Dermatological Science

Volumn 84, Issue 2, 2016, Pages 186-196

  Wang, Zhongzhi ^a   Nakamura, Kayo ^a   Jinnin, Masatoshi ^a   Kudo, Hideo ^a   Goto, Mizuki ^a   Era, Takumi ^a   Kira, Tomomi ^a   Nakashima, Taiji ^a   Fukushima, Satoshi ^a   Ihn, Hironobu ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Induced pluripotent stem cells; Systemic sclerosis

Indexed keywords

BETA INTEGRIN; CALGRANULIN A; CD51 ANTIGEN; KRUPPEL LIKE FACTOR 4; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; SMAD6 PROTEIN; TRANSCRIPTION FACTOR SOX2; TRANSFORMING GROWTH FACTOR BETA2; CD18 ANTIGEN; COLLAGEN; SMAD6 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CASE REPORT; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; INDUCED PLURIPOTENT STEM CELL; MIDDLE AGED; PATHOGENESIS; PRIORITY JOURNAL; S100A8 GENE; SCLERODERMA; SIGNAL TRANSDUCTION; SKIN FIBROBLAST; SMAD6 GENE; TGF BETA2 GENE; UPREGULATION; ANIMAL; BIOPSY; CYTOLOGY; FIBROBLAST; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MOUSE; PATHOLOGY; PHENOTYPE; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SKIN; SYSTEMIC SCLEROSIS; TERATOMA;

AGED; ANIMALS; ANTIGENS, CD18; BIOPSY; CALGRANULIN A; CELL DIFFERENTIATION; COLLAGEN; FIBROBLASTS; GENE EXPRESSION PROFILING; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MICE; MIDDLE AGED; PHENOTYPE; POLYMERASE CHAIN REACTION; SCLERODERMA, SYSTEMIC; SEQUENCE ANALYSIS, RNA; SKIN; SMAD6 PROTEIN; TERATOMA; TRANSFORMING GROWTH FACTOR BETA2;

EID: 84992697217     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2016.08.002     Document Type: Article

References (36)

1. [1] LeRoy, E.C., Smith, E.A., Kahaleh, M.B., Trojanowska, M., Silver, R.M., A strategy for determining the pathogenesis of systemic sclerosis. Is transforming growth factor β the answer?. Arthritis Rheum. 32 (1989), 817–825.
2. [2] LeRoy, E.C., Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J. Clin. Invest. 54 (1974), 880–889.
3. [3] Jimenez, S.A., Feldman, G., Bashey, R.I., Bienkowski, R., Rosenbloom, J., Co-ordinate increase in the expression of type I and type III collagen genes in progressive systemic sclerosis. Biochem. J. 237 (1986), 837–843.
4. [4] Kikuchi, K., Smith, E.A., LeRoy, E.C., Trojanowska, M., Direct demonstration of transcriptional activation of collagen gene expression in systemic sclerosis fibroblasts. Biochem. Biophys. Res. Commun. 187 (1992), 45–50.
5. [5] Ihn, H., Yamane, K., Kubo, M., Tamaki, K., Blockade of endogenous transforming growth factor β signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor β receptors. Arthritis Rheum. 44 (2001), 474–480.
6. [6] Ihn, H., The role of TGF-β signaling in the pathogenesis of fibrosis in scleroderma. Arch. Immunol. Ther. Exp. 50 (2002), 325–331.
7. [7] Asano, Y., Ihn, H., Yamane, K., Jinnin, M., Mimura, Y., Tamaki, K., Increased expression of integrin αvβ3 contributes to the establishment of autocrine TGF-β signaling in scleroderma fibroblasts. J. Immunol. 175 (2005), 7708–7718.
8. [8] Asano, Y., Ihn, H., Yamane, K., Jinnin, M., Mimura, Y., Tamaki, K., Involvement of αvβ5 integrin-mediated activation of latent transforming growth factor β1 in autocrine transforming growth factor β signaling in systemic sclerosis fibroblasts. Arthritis Rheum. 52 (2005), 2897–2905.
9. [9] Asano, Y., Ihn, H., Yamane, K., Jinnin, M., Tamaki, K., Increased expression of integrin αvβ5 induces the myofibroblastic differentiation of dermal fibroblasts. Am. J. Pathol. 168 (2006), 499–510.
10. [10] Miyoshi, N., Ishii, H., Nagai, K., Hoshino, H., Mimori, K., Tanaka, F., et al. Defined factors induce reprogramming of gastrointestinal cancer cells. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 40–45.
11. [11] Kobayashi, J., Yoshida, M., Tarui, S., Hirata, M., Nagai, Y., Kasahara, S., et al. Directed differentiation of patient-specific induced pluripotent stem cells identifies the transcriptional repression and epigenetic modification of NKX2-5, HAND1, and NOTCH1 in hypoplastic left heart syndrome. PLoS One, 9, 2014, e102796.
12. [12] Honda, N., Jinnin, M., Kajihara, I., Makino, T., Makino, K., Masuguchi, S., et al. TGF-β-mediated downregulation of microRNA-196a contributes to the constitutive upregulated type I collagen expression in scleroderma dermal fibroblasts. J. Immunol. 188 (2012), 3323–3331.
13. [13] Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee, Preliminary criteria for the classification of systemic sclerosis (scleroderma) Arthritis Rheum. 23 (1980) 581–590.
14. [14] Fusaki, N., Ban, H., Nishiyama, A., Saeki, K., Hasegawa, M., Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc. Jpn. Acad. Ser. B. Phys. Biol. Sci. 85 (2009), 348–362.
15. [15] Ban, H., Nishishita, N., Fusaki, N., Tabata, T., Saeki, K., Shikamura, M., et al. Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 14234–14239.
16. [16] Isono, K., Jono, H., Ohya, Y., Shiraki, N., Yamazoe, T., Sugasaki, A., et al. Generation of familial amyloidotic polyneuropathy-specific induced pluripotent stem cells. Stem Cell Res. 12 (2014), 574–583.
17. [17] Itoh, M., Umegaki-Arao, N., Guo, Z., Liu, L., Higgins, C.A., Christiano, A.M., Generation of 3D skin equivalents fully reconstituted from human induced pluripotent stem cells (iPSCs). PLoS One, 8, 2013, e77673.
18. [18] Yang, L., Soonpaa, M.H., Adler, E.D., Roepke, T.K., Kattman, S.J., Kennedy, M., et al. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature 453 (2008), 524–528.
19. [19] Sakoguchi, A., Nakayama, W., Jinnin, M., Wang, Z., Yamane, K., Aoi, J., et al. The expression profile of the toll-like receptor family in scleroderma dermal fibroblasts. Clin. Exp. Rheumatol., 32, 2014 (S-4-9).
20. [20] Kudo, H., Jinnin, M., Asano, Y., Trojanowska, M., Nakayama, W., Inoue, K., et al. Decreased IL-20 expression in scleroderma skin contributes to cutaneous fibrosis. Arthritis Rheumatol. 66 (2014), 1636–1647.
21. [21] Fujie, Y., Fusaki, N., Katayama, T., Hamasaki, M., Soejima, Y., Soga, M., et al. New type of Sendai virus vector provides transgene-free iPS cells derived from chimpanzee blood. PLoS One, 9, 2014, e113052.
22. [22] Jinnin, M., Ihn, H., Mimura, Y., Asano, Y., Yamane, K., Tamaki, K., Regulation of fibrogenic/fibrolytic genes by platelet-derived growth factor C a novel growth factor, in human dermal fibroblasts. J. Cell Physiol. 202 (2005), 510–517.
23. [23] Kogushi-Nishi, H., Jinnin, M., Kobayashi, Y., Muchemwa, F.C., Hirano, A., Makino, T., et al. Role of c-Jun N-terminal kinase isoforms in the cellular activity of melanoma cell lines. Clin. Exp. Dermatol. 38 (2013), 890–896.
24. [24] Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131 (2007), 861–872.
25. [25] Xu, X., Wu, W.Y., Tu, W.Z., Chu, H.Y., Zhu, X.X., Liang, M.R., et al. Increased expression of S100A8 and S100A9 in patients with diffuse cutaneous systemic sclerosis. A correlation with organ involvement and immunological abnormalities. Clin. Rheumatol. 32 (2013), 1501–1510.
26. [26] Dong, C., Zhu, S., Wang, T., Yoon, W., Li, Z., Alvarez, R.J., et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 3908–3913.
27. [27] Mori, Y., Chen, S.J., Varga, J., Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum. 48 (2003), 1964–1978.
28. [28] Asano, Y., Ihn, H., Yamane, K., Kubo, M., Tamaki, K., Impaired Smad7-Smurf-mediated negative regulation of TGF-β signaling in scleroderma fibroblasts. J. Clin. Invest. 113 (2004), 253–264.
29. [29] Banka, S., Cain, S.A., Carim, S., Daly, S.B., Urquhart, J.E., Erdem, G., et al. Leri's pleonosteosis a congenital rheumatic disease, results from microduplication at 8q22.1 encompassing GDF6 and SDC2 and provides insight into systemic sclerosis pathogenesis. Ann. Rheum. Dis. 74 (2015), 1249–1256.
30. [30] Weller, M., Constam, D.B., Malipiero, U., Fontana, A., Transforming growth factor-β2 induces apoptosis of murine T cell clones without down-regulating bcl-2 mRNA expression. Eur. J. Immunol. 24 (1994), 1293–1300.
31. [31] Hasegawa, M., Sato, S., Takehara, K., Augmented production of transforming growth factor-β by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Arch. Dermatol. Res. 296 (2004), 89–93.
32. [32] Prelog, M., Scheidegger, P., Peter, S., Gershwin, M.E., Wick, G., Sgonc, R., Diminished transforming growth factor β2 production leads to increased expression of a profibrotic procollagen α2 type I messenger RNA variant in embryonic fibroblasts of UCD-200 chickens, a model for systemic sclerosis. Arthritis Rheum. 52 (2005), 1804–1811.
33. [33] Fleischmajer, R., Perlish, J.S., Krieg, T., Timpl, R., Variability in collagen and fibronectin synthesis by scleroderma fibroblasts in primary culture. J. Invest. Dermatol. 76 (1981), 400–403.
34. [34] Mimura, Y., Ihn, H., Jinnin, M., Asano, Y., Yamane, K., Tamaki, K., Constitutive thrombospondin-1 overexpression contributes to autocrine transforming growth factor-β signaling in cultured scleroderma fibroblasts. Am. J. Pathol. 166 (2005), 1451–1463.
35. [35] Kajihara, I., Jinnin, M., Honda, N., Makino, K., Makino, T., Masuguchi, S., et al. Scleroderma dermal fibroblasts overexpress vascular endothelial growth factor due to autocrine transforming growth factor β signaling. Mod. Rheumatol. 23 (2012), 516–524.
36. [36] Jinnin, M., Makino, T., Kajihara, I., Honda, N., Makino, K., Ogata, A., et al. Serum levels of soluble vascular endothelial growth factor receptor-2 in patients with systemic sclerosis. Br. J. Dermatol. 162 (2010), 751–758.